Purpose To review the ability of current imaging technologies to provide estimates of rates of structural change in glaucoma patients.
Introduction
Glaucoma is a complex and progressive disease characterized by an optic neuropathy that is usually associated with typical visual function loss. 1 Although most glaucoma patients will show some evidence of progression, if followed long enough, the rate of deterioration can be highly variable among them. Some patients may progress slowly over the course of many years or decades with minimal impact on the quality of vision, whereas others may have aggressive disease with rapid rates of change that can eventually result in blindness or substantial impairment unless appropriate interventions take place. Therefore, the evaluation of rates of change in glaucoma is essential to allow proper allocation of resources towards the patients who are most likely to develop impairment. In fact, according to the Consensus on Medical Treatment from the World Glaucoma Association, glaucoma treatment is indicated for patients whose rates of progression will most likely result in loss in vision-related quality of life over the projected remaining years of life. 2 A complete assessment of rates of disease progression requires both structural and functional measures, as it is known that many patients seem to progress by one method and not the other. [3] [4] [5] [6] Although functional outcomes have an unquestionable relevance to patients, it has been shown that structural changes can often precede functional losses and be an earlier marker of deterioration. More importantly, a recent study showed that structural changes observed on optic disc stereophotographs are predictive of future functional losses and, therefore, carry clinically relevant prognostic information. 7 However, although optic disc stereophotographs have been considered the gold standard for evaluation of structural damage in glaucoma, evaluation of rates of structural change using stereophotographs is difficult because of the qualitative and subjective nature of this assessment.
Over the past two decades, several technologies, such as confocal scanning laser ophthalmoscopy (CSLO), scanning laser polarimetry (SLP), and optical coherence tomography (OCT), have been used to quantitatively and objectively measure the topography of the optic disc and thickness of the parapapillary retinal nerve fibre layer (RNFL). 8 Results from these imaging technologies can be used to predict glaucoma development, [9] [10] [11] [12] [13] and have the potential to detect and measure structural progression. 7, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Recent literature has focused on the ability of these instruments to provide estimates of rates of change over time. In this review, we discuss the evidence with regard to the ability of current imaging technologies in measuring rates of structural change in glaucoma and their relationship to conventional methods for assessment of disease progression.
CSLO
CSLO was introduced more than 20 years ago. It enables reproducible measurements of the surface height of the optic nerve head (ONH) and parapapillary retina. 9 The most recent implementation of this technology (Heidelberg Retina Tomograph (HRT), Heidelberg Engineering GmbH, Heidelberg, Germany) has been widely used to evaluate topographic changes of the ONH to detect progression of glaucoma. 13, [24] [25] [26] Although different stereometric parameters have been suggested as useful markers of progression, some studies have suggested that the neuroretinal rim area (RA) is the most reliable and reproducible measure for detection of change. 27, 28 Changes in RA have been demonstrated in glaucoma patients followed over time and are associated with disease progression. 14, 15, 22, [28] [29] [30] [31] [32] [33] [34] Baseline measurements obtained by the HRT have also been shown to predict future conversion to glaucoma in patients suspected of having the disease, although the predictive accuracy of the measurements on individual patients is generally low. 13 CSLO measurements have been used to evaluate rates of glaucoma progression in several studies. /year, respectively; P ¼ 0.727). The area under the receiver-operating characteristic (ROC) curve for this parameter showed a poor discriminatory ability, no better than chance. However, when eyes that had undergone glaucoma surgery were excluded, the rates of RA loss became significantly different between progressors (À0.020 mm 2 /year) and non-progressors (À0.007 mm 2 /year; P ¼ 0.015). This is probably explained by the effect of intraocular pressure (IOP) reduction in causing a significant reversal of ONH cupping, which may be interpreted as an increase in RA by the CSLO and confound evaluation of RA change in patients who underwent surgery during follow-up. 29, 37, 38 A shortcoming of the CSLO technology stems from the variation induced by tracing a contour line to outline the optic disc. Alternative approaches for detecting progression in series of CSLO images, such as the topographic change analysis, 26, 31, 39, 40 the glaucoma probability score, 14, 25, 41, 42 and statistic image mapping, 43, 44 have been developed and obviate the need for a contour line. These methods, however, exhibit only moderate agreement with each other and have poor agreement with expert-assessed change in optic disc stereophotographs. 45 In the context of detecting progressive glaucoma, one advantage of the CSLO, when comparing it to other imaging devices, is that latest commercially available versions of the instrument have shown relatively good compatibility with older ones, which is of significant benefit to clinicians and researchers who need to follow up patients for long periods of time.
SLP SLP (GDx; Carl Zeiss Meditec Inc., Dublin, CA, USA) is a confocal scanning laser ophthalmoscope with an integrated polarimeter that measures the amount of retardation (phase shift) of a polarized near-infrared laser beam as it passes through the RNFL. 45 Changes in RNFL have been suggested to be the earliest sign of glaucoma development in many patients and to precede visual field loss. 46 The SLP enables clinicians to evaluate the parapapillary RNFL objectively and quantitatively. This technology has been shown to provide reproducible RNFL measurements and to differentiate glaucoma patients from normal subjects with sensitivities and specificities between 72 and 78%, and 56 and 92%, respectively. [47] [48] [49] [50] [51] [52] Imaging artifacts such as a poorly compensated corneal birefringence can hamper the accuracy of the device in clinical practice. 53 The introduction of a variable corneal polarization compensator (GDxVCC) attempted to alleviate this problem and resulted in improved diagnostic accuracy. 54 The GDxVCC scans, however, were found to be limited by atypical retardation patterns (ARPs). ARPs result from poor noise-to-signal ratio as a consequence of light scattering in the eye. Medeiros et al 18 have shown that the presence of ARP on SLP scans adversely affects the detection of progressive glaucomatous RNFL loss. The most recent commercially available version (GDxPRO) is a modification of the GDxVCC and provides an enhanced corneal compensation (ECC) to eliminate artifacts associated with ARP. 54, 55 The GDx software has been recently upgraded with the addition of a guided progression analysis (GPA). The GPA software compares SLP images acquired during follow-up and reports a summary analysis for progression in an individual eye after automated consideration of the expected test-retest variability. It has been shown to be able to identify a significant proportion of glaucoma progression with 50% sensitivity and 96% specificity compared with optic disc stereophotographs and visual fields. 16 Repeatability of GDxVCC was demonstrated to be stable for all stages of disease severity with a repeatability coefficient within 4 mm (compared with 6 mm with Stratus OCT, Carl Zeiss Meditec Inc.). (Figure 2 ). 59 The same investigators in a subsequent publication reported an average rate of decline for RNFL thickness measurements of À1.24 mm/year in progressors vs À0.34 mm/year in non-progressors, with a significantly higher area under the ROC curve for detecting change for ECC compared with VCC (0.89 vs 0.65; Po0.001) (Figure 3) . 21 Grewal . .
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Eye et al 57 demonstrated that ECC identified more cases of progression than VCC (11.8 vs 8.8%), with only moderate agreement (k ¼ 0.57). In a subsequent publication, 58 the same investigators using ECC found rates of annual RNFL loss of À1.11 mm/year (progressors) vs À0.41 mm/year (non-progressors), when progression was defined based on the SAP visual field index.
A significant limitation of SLP is the lack of interchangeability among serial generations of the commercial instrument. RNFL thickness measurements obtained with the GDxVCC and GDxECC are not interchangeable. Thus, a new baseline must be established in the case of conversion to GDxECC.
OCT
OCT is a non-contact and non-invasive technique for examination of the human retina. Briefly, the instrument uses a super luminescent diode light and works similar to a B-scan ultrasound, using light instead of sound. Unlike the CSLO and the SLP, OCTs are currently available from several different manufactures, with different axial resolution and lower acquisition time. We focus, herein, on the Stratus OCT because very little longitudinal data are currently available for the spectral-domain OCTs.
Wollstein et al 60 showed the potential use of OCT in detecting glaucomatous progression with an event-based approach (ie, a change greater than the expected variability was considered progression). Using a prototype, they concluded that the OCT was more sensitive than standard visual fields for the detection of progression. In fact, 22% of eyes had a significant change measured by the OCT without corresponding deterioration of the visual fields. However, it was not clear whether these eyes were true progressors undetected by visual fields or false positives due to variability of the measurements or age-related thinning of the RNFL.
Medeiros et al 20 evaluated the ability of RNFL thickness, ONH, and macular thickness measurements to detect glaucomatous progression. In their study, progression was determined by SAP and longitudinal assessment of optic disc stereophotographs. They reported the RNFL thickness parameters as having better ability than ONH and macular thickness parameters to detect progression (Figure 4 ). This is in agreement with previous cross-sectional studies that showed a poor performance of Stratus OCT-derived macular and ONH parameters for cross-sectional detection of glaucoma. 61 For average RNFL thickness, a rate of change of À0.72 mm (B1%)/year for the progressors compared with 0.14 mm/year in non-progressors was reported. The authors found a wide variation of rates of change, which has also been reported by Leung et al 62 in a study evaluating the GPA software of Stratus OCT. Although this wide range can be explained by individual characteristics, such as stage of disease and response to treatment, it is possible that non-centered scans and signal strength affected the ability to detect change. 63, 64 Nonetheless, the wide individual variation should be considered when evaluating patients on a case-by-case basis. 
Eye
The recent introduction of spectral domain OCT (SDOCT) has enhanced resolution and decreased scan acquisition time compared with Stratus OCT. With more reproducible images, 65, 66 there is potential for improved ability to detect glaucomatous progression. Further, with this higher resolution, new scan types are now possible. One example is the ganglion cell complex (GCC) that selectively measures the inner retina in the macular region. The GCCs have shown similar diagnostic accuracy for detecting glaucoma as the RNFL thickness, and may be useful for monitoring the disease. 67 Recently, Leung et al (Leung CK et al, personal communication) evaluated the ability to detect RNFL progression using Stratus OCT and SDOCT. A total of 128 eyes were followed for a minimum of 24 months. They found more progressors using SDOCT compared with Stratus OCT (23.5% of patients with SDOCT vs 4.9% with Stratus OCT). The agreement with visual field progression was also better with SDOCT. In addition, five eyes had an increasing RNFL thickness with Stratus OCT, indicating an inherent measurement variability of the instrument. The agreement for detection of RNFL progression was poor between the two instruments (k ¼ 0.188). The rate of change ranged between À1.52 and À5.03 mm/year with SDOCT, and between À2.22 and À7.60 mm/year with Stratus OCT. Table 1 summarizes the ability of all the three imaging technologies to provide rates of change.
Summary and future directions
Currently available imaging technologies have been demonstrated to detect and quantify glaucomatous progression in a reproducible manner. Rates of change in RNFL thickness and optic disc topographic measurements as measured by different instruments have been shown to correlate significantly with conventional methods for assessment of change, such as SAP and optic disc stereophotographs. Several studies have shown that rates of structural damage are faster in eyes with progressive glaucoma, and show a correlation with important risk factors for the disease such as IOP.
Advances in the assessment of change with imaging devices may shift the macroscopic standard of optic disc photographs towards the microscopic and three-dimensional imaging of the retinal layers. With the increasing resolution and reliability of imaging technologies, it is likely that the estimation of these rates of change will be more precise and individualized in the near future. In addition, advances and implementation of image stabilization technologies should improve reproducibility of structural measurements to enable better differentiation of variability from true progression.
At present, the Food and Drug Administration (FDA) recognizes IOP as an efficacy end point for IOP-lowering drugs and visual field testing, visual acuity, contrast sensitivity, and colour vision as functional end points. 68 IOP is an imperfect surrogate for the clinical outcomes of glaucoma, as disease can progress despite low IOP or remain stable despite IOP levels considered high. [69] [70] [71] The use of visual fields as an end point is potentially limited by the need for large samples, long follow-up, variability of results, and inconsistency in criteria for defining progression. 72 The absence of regulatory support for other glaucoma end points has been identified as a weakness in exploring candidate agents for neuroprotective therapy and alternative surrogate end points have been sought. Structural measurements obtained by imaging technologies have the potential to overcome these obstacles, and could potentially act as useful biomarkers and surrogate end points to be used in glaucoma clinical trials. Future research should be directed at evaluating, quantifying, and comparing the abilities of structural change measured by different imaging technologies in predicting clinically relevant outcomes in glaucoma. 
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